Follow Mangoceuticals to never miss an important update.
Mangoceuticals reported zero revenue for the quarter, down from the small amount of sales it generated last year. The company lost 9 cents per share, which is a significant loss for a business of this size. These results reflect a company that has essentially stopped operating its original telemedicine brand to focus on its planned merger with Nuclea Energy.
This confirms that the original business is no longer a source of value. For the stock to be worth anything, the company must successfully close its merger and find a way to fund its new goal of building small nuclear reactors. This is a high-risk transition for a firm that is currently losing money with no sales coming in.
Nuclea Energy has agreed to buy nuclear technology assets from Moltex Energy, including designs for a stable salt reactor and fuel recycling tech. This research has previously received about 96 million Canadian dollars in funding from private investors and government agencies. This adds real intellectual property to the company Nuclea is building.
For Mangoceuticals owners, this deal matters because Nuclea is the company they are preparing to merge with. While the technology is advanced and has a long history of development, it will still require massive amounts of cash to turn these designs into working power plants. The success of this acquisition depends entirely on the merger closing and the combined company finding new ways to raise money.
Source: GlobeNewsWire
The company is expected to report its latest quarterly numbers today. While Mangoceuticals started as a men's health brand, the focus has shifted entirely to its planned merger with Nuclea Energy to build micro-nuclear reactors. The most important things to watch are the company's cash levels and any updates on the merger timeline. The original health business has been losing significant amounts of money, so the path forward depends almost entirely on successfully closing this deal and finding a way to fund its new energy ambitions.
No Wall Street analysts cover Mangoceuticalsyet. That’s common for smaller companies. We’ll show their price targets here once coverage begins.
Follow Mangoceuticals to get the latest and most important updates.
Follow MGRX